Home Cart 0 Sign in  
X

[ CAS No. 83664-33-9 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 83664-33-9
Chemical Structure| 83664-33-9
Chemical Structure| 83664-33-9
Structure of 83664-33-9 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 83664-33-9 ]

Related Doc. of [ 83664-33-9 ]

Alternatived Products of [ 83664-33-9 ]

Product Details of [ 83664-33-9 ]

CAS No. :83664-33-9 MDL No. :MFCD09037462
Formula : C12H10BrNO Boiling Point : -
Linear Structure Formula :- InChI Key :LXKTVNFZAFTUNZ-UHFFFAOYSA-N
M.W : 264.12 Pubchem ID :11108191
Synonyms :

Calculated chemistry of [ 83664-33-9 ]

Physicochemical Properties

Num. heavy atoms : 15
Num. arom. heavy atoms : 12
Fraction Csp3 : 0.08
Num. rotatable bonds : 3
Num. H-bond acceptors : 2.0
Num. H-bond donors : 0.0
Molar Refractivity : 62.92
TPSA : 22.12 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : Yes
CYP2C9 inhibitor : No
CYP2D6 inhibitor : Yes
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.54 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.49
Log Po/w (XLOGP3) : 3.34
Log Po/w (WLOGP) : 3.27
Log Po/w (MLOGP) : 2.83
Log Po/w (SILICOS-IT) : 3.52
Consensus Log Po/w : 3.09

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -3.98
Solubility : 0.0279 mg/ml ; 0.000106 mol/l
Class : Soluble
Log S (Ali) : -3.48
Solubility : 0.0871 mg/ml ; 0.00033 mol/l
Class : Soluble
Log S (SILICOS-IT) : -5.54
Solubility : 0.00076 mg/ml ; 0.00000288 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 0.0
Synthetic accessibility : 2.09

Safety of [ 83664-33-9 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 83664-33-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 83664-33-9 ]
  • Downstream synthetic route of [ 83664-33-9 ]

[ 83664-33-9 ] Synthesis Path-Upstream   1~15

  • 1
  • [ 83664-33-9 ]
  • [ 13466-38-1 ]
Reference: [1] Journal of the American Chemical Society, 1949, vol. 71, p. 70,73
  • 2
  • [ 13466-38-1 ]
  • [ 100-39-0 ]
  • [ 83664-33-9 ]
YieldReaction ConditionsOperation in experiment
95% With silver carbonate In benzene at 50℃; for 24 h; To a solution of 5-bromopyridin-2 (1E-ONE (100 mmol, 17. 4 g, 1. 0 eq.) in benzene (170 mL) was added silver (I) carbonate (67. 0 mmol, 18. 5 g, 0. 67 eq.). The flask was wrapped with aluminum foil and then benzyl bromide (120 mmol, 20. 5 g, 1. 2 eq.) was added via syringe in a steady stream. The mixture was heated to 50 °C and stirred in the dark for approximately 24 hours. LC/MS of the reaction mixture indicates two peaks both with M+H = 265 corresponding to the desired molecular weight. On the basis of relative polarities, the more polar peak was thought to be the N-alkylated product and consisted of approximately 20 percent of the total. The reaction mixture was allowed to cool to room temperature and the silver salt was removed by filtration of the mixture through a pad of celite. The filter cake was washed with benzene and the organic layer was washed twice with 2percent sodium bicarbonate and twice with water. The organic layer was dried over magnesium sulfate and concentrated in vacuo. The crude residue was purified on a Biotage Sp4 65i over a gradient of 5-95percent hexanes in ethyl acetate to afford the title compound as a golden oil (25. 1 g, 95percent). LRMS : 265 (M+H) +. H NMR (DMSO-D6, 400 MHz) ; 8. 29 (1 H, s) 7. 72 (1 H, D, J=8. 5 Hz) 7. 31-7. 43 (5 H, m) 6. 54 (1 H, d, J=8. 5Hz) 5. 34 (2 H, s)
95% With silver carbonate In toluene at 100℃; To a solution of 5-bromopyridin-2(1 H)-one (1.28 g, 7.36 mmol) and Ag2CO3 (3 g, 11.04 mmol) in toluene (50 mL) was added (bromomethyl)benzene (1.25 g, 7.36 mmol) dropwiseand the reaction mixture was stirred at 100 °C over night. The reaction mixture was filteredthrough a short pad of silica gel and washed with DCM. The filtrate was concentrated to yield the title compound as light yellow oil (1 .8 g, 95percent).
95% With silver carbonate In toluene at 100℃; To a solution of 5-bromopyridin-2(1H)-one (1.28 g, 7.36 mmol) and Ag2CO3 (3 g, 11.04 mmol) in toluene (50 mL) was added (bromomethyl)benzene (1.25 g, 7.36 mmol) dropwise and the reaction mixture was stirred at 100° C. over night. The reaction mixture was filtered through a short pad of silica gel and washed with DCM. The filtrate was concentrated to yield the title compound as light yellow oil (1.8 g, 95percent).
85% With silver carbonate In tetrahydrofuranReflux; Darkness To a solution of 1 (1.4 g, 8 mmol) in dry THF (80 mL) was added benzyl bromide (1.14 mL, 9.6 mmol) and Ag2CO3 (1.32 g, 4.8 mmol) and subsequently refluxed in the dark overnight. The reaction mixture was filtered through celite and concentrated to provide brown solid which was flash chromatographed on silica gel eluting with 10percent EtOAc in hexanes to provide 1.8 g (85percent) of a white solid;1H NMR (CDCl3) δ (ppm) 5.34 (s, 2H), 6.71 (d, 1H, J = 8.7 Hz), 7.25-7.44 (m, 5H), 7.64 (dd, 1H, J = 8.8 Hz), 8.20 (d, 1H, J = 2.5 Hz); MS (ESI) m/z 289 (M+Na)+.

Reference: [1] Heterocycles, 1990, vol. 31, # 5, p. 819 - 824
[2] Patent: WO2004/92145, 2004, A1, . Location in patent: Page 148-149
[3] Patent: WO2014/13469, 2014, A1, . Location in patent: Page/Page column 37; 38
[4] Patent: US2014/163036, 2014, A1, . Location in patent: Paragraph 0204-0205
[5] Tetrahedron Letters, 2005, vol. 46, # 27, p. 4621 - 4625
[6] Bioorganic and Medicinal Chemistry, 2011, vol. 19, # 20, p. 5924 - 5934
  • 3
  • [ 624-28-2 ]
  • [ 100-51-6 ]
  • [ 83664-33-9 ]
YieldReaction ConditionsOperation in experiment
92% With potassium hydroxide In toluene for 1.5 h; Heating / reflux A mixture of 2,5-dibromopyridine (20 g, 84.4 MMOL), DIBENZO-18-CROWN-6 (1.5 g, 4. 2mmol), benzyl alcohol (11. 9 g, 11.4 mL, 109.8 mmol), potassium hydroxyde (11. 4 g, 202.6 mmol) and toluene (200 mL) was atirred at reflux with a Dean-Stark apparatus for 1.5 hours. After removal of solvent in reduced pressure, the residue was diluted with water, and extracted with chloroform. The separated organic phase was dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by column chromatography on silica-gel, (hexane: ethyl acetate, 98: 2) followed by recrystallization from hexane, to give 2- (BENZYLOXY)-5- bromopyridine (20.6 g, 92percent) as a colorless solid.
92% With potassium hydroxide In toluene for 1.5 h; Heating / reflux under azeotropic conditions A mixture of 2,5-dibromopyridine (20.0 g, 84.4 mmol), dibenzo-18-crown-6 (1.5 g, 4.2 mmol), benzyl alcohol (11.9 g, 11.4 mL, 109.8 mmol) and KOH (11.4 g, 202.6 mmol) in toluene (200 mL) was refluxed with Dean-Stark for 1.5 hours. After removal of solvent under reduced pressure, the residue was diluted with water, and extracted with chloroform. The separated organic phase was dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude oil was purified by column chromatography on silica-gel, (hexane:ethyl acetate, 98:2) followed by recrystallization from hexane, to give 2-benzyloxy-5-bromopyridine (20.6 g, 92 percent) as a colorless solid.
90%
Stage #1: With sodium hydride In N,N-dimethyl-formamide at 0 - 20℃; for 0.5 h;
Stage #2: at 0 - 20℃; for 1 h;
Manufacturing Example 12-1-1 2-Benzyloxy-5-bromopyridine; To a solution of phenyl-methanol (20.5 g, 190 mmol) in N,N-dimethylformamide (200 mL) was added sodium hydride (7.6 g, 190 mmol) under nitrogen atmosphere on an ice bath (0° C.), which was stirred for 30 minutes at room temperature. 2,5-Dibromopyridine was then added thereto on the ice bath (0° C.), and stirred for 60 minutes at room temperature. The reaction mixture was partitioned into is water and ethyl acetate on the ice bath (0° C.). The organic layer was washed with water and saturated aqueous sodium chloride, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under a reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:heptane=1:20 then 1:10) to obtain the title compound (15.1 g, 90percent).1H-NMR Spectrum (CDCl3) δ (ppm): 5.34 (2H, s), 6.71-6.73 (1H, m), 7.32-7.45 (5H, m), 7.64-7.67 (1H, m), 8.20-8.21 (1H, m).
90%
Stage #1: With sodium hydride In N,N-dimethyl-formamide at 0 - 20℃; for 0.5 h;
Stage #2: at 0 - 20℃; for 1 h;
To a solution of phenyl-methanol (20.5 g, 190 mmol) in N,N-dimethylformamide (200 mL) was added sodium hydride (7.6 g, 190 mmol) under nitrogen atmosphere on an ice bath (0° C.), which was stirred for 30 minutes at room temperature. 2,5-Dibromopyridine was then added thereto on the ice bath (0° C.), and stirred for 60 minutes at room temperature. The reaction mixture was partitioned into water and ethyl acetate on the ice bath (0° C.). The organic layer was washed with water and saturated aqueous sodium chloride, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under a reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:heptane=1:20 then 1:10) to obtain the title compound (15.1 g, 90percent). 1H-NMR Spectrum (CDCl3) δ (ppm): 5.34 (2H, s), 6.71-6.73 (1H, m), 7.32-7.45 (5H, m), 7.64-7.67 (1H, m), 8.20-8.21 (1H, m).
85% With potassium hydroxide In toluene for 3 h; Heating / reflux A suspension of 2, 5-dibromopyridine (2.0 g, 8.4 mmol), dibenzo-18-crown-6 (0.14 g, . 05 equiv), benzyl alcohol (1.1 mL, 1.3 equiv), and potassium hydroxide [(1. 1] g, 2.4 equiv) in toluene (30 mL) were heated at reflux for 3 h in an apparatus fitted with a Dean-Stark trap. The suspension was cooled, concentrated, suspended in water, and extracted into methylene chloride. The combined organic phases were washed with water, then brine, dried over magnesium sulfate, and concentrated to give 1.9 g (85percent) which was used without purification. Mass spec.: 264.25 (MH) [+.]
71.2%
Stage #1: With sodium hydride In N,N-dimethyl-formamide at 0℃; for 1 h;
Stage #2: at 20℃;
To a solution of sodium hydride (1.04 g, 26.0 mmol, 1.3 equiv)In N, N-dimethylformamide (30 ml) was added benzyl alcohol (2.59 g, 24.0 mmol, 1.2 equiv)The mixture was stirred at 0 ° C for 1 hour,Followed by the addition of 2,5-dibromopyridine (4.74 g, 20 mmol, 1.0 equiv)The reaction solution was allowed to react overnight at room temperature.The reaction was diluted with ethyl acetate (300 mL), washed with half-saturated brine (300 mL x 4) and the organic phase was dried over anhydrous sodium sulfate. The filtrate was chromatographed three times with petroleum ether and the residue was purified by column chromatography (Eluent: petroleum ether: ethyl acetate = 200: 1) to give 2- (benzyloxy) -5-bromopyridine (3.76 g, yield: 71.2percent).

Reference: [1] Journal of Organic Chemistry, 1995, vol. 60, # 5, p. 1408 - 1412
[2] Polyhedron, 2013, vol. 52, p. 755 - 760
[3] Patent: WO2004/43926, 2004, A1, . Location in patent: Page 150
[4] Patent: WO2004/69805, 2004, A1, . Location in patent: Page 55
[5] Patent: US2009/82403, 2009, A1, . Location in patent: Page/Page column 66
[6] Patent: US2007/105904, 2007, A1, . Location in patent: Page/Page column 62-63
[7] Patent: WO2003/104236, 2003, A1, . Location in patent: Page 168-169
[8] Patent: CN106588937, 2017, A, . Location in patent: Paragraph 0196
[9] Patent: WO2004/814, 2003, A1, . Location in patent: Page 61; 62
[10] Patent: US2004/102472, 2004, A1, . Location in patent: Page 38
  • 4
  • [ 13466-38-1 ]
  • [ 100-39-0 ]
  • [ 83664-33-9 ]
YieldReaction ConditionsOperation in experiment
99%
Stage #1: With sodium hydride In N,N-dimethyl-formamide for 0.0833333 h; Inert atmosphere; Cooling with ice
Stage #2: at 20℃; for 1 h;
Example 117; Preparation of 5-(2-(benzyloxy)pyridin-5-yl)-3-(3-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-2-propylphenoxy)benzyl)-5-methylimidazolidine-2,4-dione; 117-a) Preparation of 5-(2-(benzyloxy)pyridin-5-yl)-5-methylimidazolidine-2,4-dione; 117-a-1) Preparation of 5-bromo-2-(benzyloxy)pyridine; 2-Hydroxy-5-bromopyridine (1.00 g, 5.75 mmol) was dissolved in N,N'-dimethylformamide (23 mL), and the resultant mixture was added with sodium hydride (purity 50percent) (253 mg, 6.32 mmol) under an argon atmosphere under ice-cold conditions. Five minutes later, the resultant mixture was added with benzyl bromide (6.82 mL, 6.90 mmol) at the same temperature, and stirred at room temperature for 1 hour. Under ice-cold conditions, the reaction solution was added with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, then concentrated in vacuo, and purified using silica-gel column chromatography (n-hexane/ethyl acetate=1/1). 5-Bromo-2-(benzyloxy)pyridine (1.51 g, yield 99percent) was obtained as a pale yellow solid.1H-NMR (CDCl3) δ: 5.10 (2H, s), 6.54 (1H, d, J=9.5 Hz), 7.28-7.39 (7H, m).
Reference: [1] Patent: US2010/48610, 2010, A1, . Location in patent: Page/Page column 66
[2] European Journal of Organic Chemistry, 2007, # 24, p. 4038 - 4049
[3] Patent: WO2009/70869, 2009, A1, . Location in patent: Page/Page column 45
[4] Patent: WO2007/84560, 2007, A2, . Location in patent: Page/Page column 158
  • 5
  • [ 13466-38-1 ]
  • [ 100-44-7 ]
  • [ 83664-33-9 ]
YieldReaction ConditionsOperation in experiment
92% With N-ethyl-N,N-diisopropylamine; zinc(II) oxide; zinc(II) chloride In 1,4-dioxane at 110℃; Inert atmosphere General procedure: To a solution of substituted 2-oxo-1,2-dihydropyridines (3.36 mmol), zinc oxide (0.30 g, 3.70 mmol),zinc chloride (0.50 g, 3.70 mmol), N,N-diisopropylethylamine (0.48 g, 3.70 mmol), 1,4-dioxane (15 mL)was added benzyl chloride (0.58 g, 4.04 mmol) under argon atmosphere. The mixture was heated in 110 °C oil bath with rapid stirring for the indicated time. The reactor was cooled to room temperature,and the insoluble residue was filtered off through celite, and the cake was wash with ethyl acetate(30 mL). The filtrate was washed with water (10 mL 2), once with brine (10 mL), dried overmagnesium sulfate, filtered, and concentrated in vacuo to afford crude product. The product was purified by column chromatography on silica gel (ethyl acetate: petroleum ether = 1:20) to yield thecorresponding compounds.
Reference: [1] Molecules, 2018, vol. 23, # 7,
  • 6
  • [ 624-28-2 ]
  • [ 83664-33-9 ]
Reference: [1] Patent: EP1439175, 2004, A1, . Location in patent: Page 46-47
  • 7
  • [ 13466-38-1 ]
  • [ 100-44-7 ]
  • [ 83664-33-9 ]
  • [ 217448-53-8 ]
Reference: [1] Organic Letters, 2015, vol. 17, # 14, p. 3382 - 3385
  • 8
  • [ 13466-38-1 ]
  • [ 100-39-0 ]
  • [ 83664-33-9 ]
  • [ 217448-53-8 ]
Reference: [1] Organic Letters, 2015, vol. 17, # 14, p. 3382 - 3385
  • 9
  • [ 766-11-0 ]
  • [ 100-51-6 ]
  • [ 83664-33-9 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2008, vol. 18, # 12, p. 3565 - 3569
  • 10
  • [ 39856-50-3 ]
  • [ 100-51-6 ]
  • [ 83664-33-9 ]
Reference: [1] Journal of Organic Chemistry, 2008, vol. 73, # 23, p. 9326 - 9333
  • 11
  • [ 13466-38-1 ]
  • [ 100-39-0 ]
  • [ 83664-33-9 ]
Reference: [1] Patent: US2005/187266, 2005, A1,
  • 12
  • [ 83664-33-9 ]
  • [ 106984-91-2 ]
Reference: [1] Polyhedron, 2013, vol. 52, p. 755 - 760
  • 13
  • [ 83664-33-9 ]
  • [ 68-12-2 ]
  • [ 635712-99-1 ]
YieldReaction ConditionsOperation in experiment
100%
Stage #1: With n-butyllithium In tetrahydrofuran at -78℃; for 1 h;
Stage #2: for 0.5 h;
To a solution of [2-BENZYLOXY-5-BROMO-PYRIDINE] (1.64 g, 6.2 mmol) in tetrahydrofuran (25 [ML,-78°C)] was added n-butyllithium (2.5 M in hexane, 2.61 mL, 1.05 equiv). After 1 h [AT-78°C,] dimethylformamide (0.97 mL, 2 equiv) was added and the mixture stirred for 30 min. The reaction was quickly poured into a stirred solution of 5percent aqueous sodium bicarbonate (50 [ML)] and extracted with diethyl ether [(-3X).-THE ETHEREAL-WAS WASHED-WITH BRINE, DNeD-OVER MaGNESIUM~SULFATE, AND] concentrated to give 1.16 g (quant. ) which was used without purification. Mass spec.: 186.34 [(MH)] [+.]
73%
Stage #1: With n-butyllithium In tetrahydrofuran at -78℃; for 1 h;
Stage #2: at -78℃; for 0.5 h;
n-Butyl lithium (2. 5M, 95. 9 mmol, 38. 4 mL, 1. 05 eq.) was added dropwise via syringe to a stirred solution OF 2- (BENZYLOXY)-5-BROMOPYRIDINE (91. 3 mmol, 24. 1 G, 1. 0 eq.) in THF (260 mL, c = 0. 35) cooled to-78 °C. Upon completion of addition, the solution was allowed to continue stirring at the same low temperature for 1 hour. At this point, NN-dimethylformamide (183 mmol, 13. 4 G, 2. 0 eq.) was added dropwise as a solution in 5 mL THF. Stirring was continued at the same low temperature for a further 30 minutes at which point the reaction was quenched by addition of 5percent sodium bicarbonate. The mixture was transferred to a separatory funnel and extracted with ether (3 x 250 mL). The combined organic layers were washed with brine, dried over anhydrous magnesium sulfate and concentrated in vacuo. The resultant yellow oil was purified on a Biotage Sp4 65i over a gradient OF 0-50percent hexanes in ethyl acetate to afford the title compound (14. 1 g, 73percent). LRMS : 214 (M+H) +. 'H NMR (DMSO-D6, 400 MHz) ; 10. 02 (1 H, s) 8. 86 (1 H, s) 8. 03 (1 H, d, J=9. 3 Hz) 7. 31-7. 43 (5 H, m) 6. 50 (1 H, d, J=9. 3 HZ) 5. 33 (2 H, s)
40%
Stage #1: With n-butyllithium In tetrahydrofuran; hexane at -78℃; for 0.5 h;
Stage #2: at -78 - 20℃; for 0.5 h;
Manufacturing Example 12-1-2 6-Benzyloxy-pyridin-3-carbaldehyde; To a solution of 2-benzyloxy-5-bromopyridine (15.1 g, 57.0 mmol) described in Manufacturing Example 12-1-1 in anhydrous tetrahydrofuran (250 mL) were added dropwise n-butyl lithium (2.67 M n-hexane solution, 25.6 mL, 68.4 mmol) under nitrogen atmosphere on a dry ice-ethanol bath (-78° C.), which was stirred for 30 minutes at -78° C. N,N-Dimethylformamide (6.60 mL, 85.5 mmol) was then added thereto at -78° C, and stirred for 30 minutes. Water and ethyl acetate were added to the reaction mixture, and the organic layer was separated after stirring for 10 minutes at room temperature. The organic layer was washed with water and saturated aqueous sodium chloride, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under a reduced pressure. The residue was purified by NH silica gel column chromatography (ethyl acetate:heptane=1:7 then 1:5) to obtain the title compound (4.87 g, 40percent).1H-NMR Spectrum (CDCl3) δ (ppm): 5.49 (2H, s), 6.89-6.92 (1H, m), 7.34-7.48 (5H, m), 8.07-8.10 (1H, m), 8.64-8.65 (1H, m), 9.97 (1H, s).
40%
Stage #1: With n-butyllithium In tetrahydrofuran; hexane at -78℃; for 0.5 h;
Stage #2: at -78℃; for 0.5 h;
To a solution of 2-benzyloxy-5-bromopyridine (15.1 g, 57.0 mmol) described in Manufacturing Example 12-1-1 in anhydrous tetrahydrofuran (250 mL) were added dropwise n-butyl lithium (2.67 M n-hexane solution, 25.6 mL, 68.4 mmol) under nitrogen atmosphere on a dry ice-ethanol bath (-78° C.), which was stirred for 30 minutes at -78° C. N,N-Dimethylformamide (6.60 mL, 85.5 mmol) was then added thereto at -78° C., and stirred for 30 minutes. Water and ethyl acetate were added to the reaction mixture, and the organic layer was separated after stirring for 10 minutes at room temperature. The organic layer was washed with water and saturated aqueous sodium chloride, and dried over anhydrous magnesium sulfate, and the solvent was evaporated under a reduced pressure. The residue was purified by NH silica gel column chromatography (ethyl acetate:heptane=1:7 then 1:5) to obtain the title compound (4.87 g, 40percent). 1H-NMR Spectrum (CDCl3) δ (ppm): 5.49 (2H, s), 6.89-6.92 (1H, m), 7.34-7.48 (5H, m), 8.07-8.10 (1H, m), 8.64-8.65 (1H, m), 9.97 (1H, s).

Reference: [1] Patent: WO2003/104236, 2003, A1, . Location in patent: Page 169
[2] Polyhedron, 2013, vol. 52, p. 755 - 760
[3] Journal of Medicinal Chemistry, 2014, vol. 57, # 6, p. 2536 - 2548
[4] Patent: WO2004/92145, 2004, A1, . Location in patent: Page 149
[5] Patent: US2009/82403, 2009, A1, . Location in patent: Page/Page column 66
[6] Patent: US2007/105904, 2007, A1, . Location in patent: Page/Page column 63
  • 14
  • [ 83664-33-9 ]
  • [ 144-55-8 ]
  • [ 635712-99-1 ]
Reference: [1] Patent: US2004/204397, 2004, A1,
  • 15
  • [ 83664-33-9 ]
  • [ 73183-34-3 ]
  • [ 832735-54-3 ]
YieldReaction ConditionsOperation in experiment
59.5% With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium acetate In 1,4-dioxane at 100℃; Inert atmosphere To a solution of 2- (benzyloxy) -5-bromopyridine (compound 204-9) (3.76 g, 14.2 mmol, 1.0 equiv)(Compound No. 205) (4.34 g, 17.1 mmol, 1.2 equiv) was added to a solution of 1,4-dioxane (50 mL)Potassium acetate (3.48 g, 35.5 mmol,2.5 equivalents) and [1,1'-bis (diphenylphosphino) ferrocene] palladium dichloride (1.16 g, 1.4 mmol, 0.1 equiv)The reaction solution was heated under reflux with nitrogen under reflux to 100 ° C overnight.The reaction was taken dry and the residue was purified by column chromatography (eluent: petroleum ether: dichloromethane = 2: 1)To give 2- (benzyloxy) -5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) pyridine(2.63 g, yield: 59.5percent).
Reference: [1] Patent: CN106588937, 2017, A, . Location in patent: Paragraph 0197
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 83664-33-9 ]

Aryls

Chemical Structure| 960298-00-4

[ 960298-00-4 ]

2-(Benzyloxy)-4-bromopyridine

Similarity: 0.89

Chemical Structure| 126717-60-0

[ 126717-60-0 ]

5-Bromo-2-benzyloxy-6-methylpyridine

Similarity: 0.86

Chemical Structure| 59717-96-3

[ 59717-96-3 ]

5-Bromo-2-phenoxypyridine

Similarity: 0.79

Chemical Structure| 1214900-01-2

[ 1214900-01-2 ]

2-(Benzyloxy)pyridin-4-amine

Similarity: 0.77

Chemical Structure| 635712-99-1

[ 635712-99-1 ]

6-(Benzyloxy)nicotinaldehyde

Similarity: 0.77

Bromides

Chemical Structure| 960298-00-4

[ 960298-00-4 ]

2-(Benzyloxy)-4-bromopyridine

Similarity: 0.89

Chemical Structure| 164513-39-7

[ 164513-39-7 ]

5-Bromo-2-methoxy-4-methylpyridine

Similarity: 0.87

Chemical Structure| 126717-60-0

[ 126717-60-0 ]

5-Bromo-2-benzyloxy-6-methylpyridine

Similarity: 0.86

Chemical Structure| 870521-31-6

[ 870521-31-6 ]

5-Bromo-2-isopropoxypyridine

Similarity: 0.85

Chemical Structure| 760207-87-2

[ 760207-87-2 ]

5-Bromo-2-methoxy-3-methylpyridine

Similarity: 0.85

Ethers

Chemical Structure| 960298-00-4

[ 960298-00-4 ]

2-(Benzyloxy)-4-bromopyridine

Similarity: 0.89

Chemical Structure| 164513-39-7

[ 164513-39-7 ]

5-Bromo-2-methoxy-4-methylpyridine

Similarity: 0.87

Chemical Structure| 126717-60-0

[ 126717-60-0 ]

5-Bromo-2-benzyloxy-6-methylpyridine

Similarity: 0.86

Chemical Structure| 870521-31-6

[ 870521-31-6 ]

5-Bromo-2-isopropoxypyridine

Similarity: 0.85

Chemical Structure| 760207-87-2

[ 760207-87-2 ]

5-Bromo-2-methoxy-3-methylpyridine

Similarity: 0.85

Related Parent Nucleus of
[ 83664-33-9 ]

Pyridines

Chemical Structure| 960298-00-4

[ 960298-00-4 ]

2-(Benzyloxy)-4-bromopyridine

Similarity: 0.89

Chemical Structure| 164513-39-7

[ 164513-39-7 ]

5-Bromo-2-methoxy-4-methylpyridine

Similarity: 0.87

Chemical Structure| 126717-60-0

[ 126717-60-0 ]

5-Bromo-2-benzyloxy-6-methylpyridine

Similarity: 0.86

Chemical Structure| 870521-31-6

[ 870521-31-6 ]

5-Bromo-2-isopropoxypyridine

Similarity: 0.85

Chemical Structure| 760207-87-2

[ 760207-87-2 ]

5-Bromo-2-methoxy-3-methylpyridine

Similarity: 0.85